Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
Tanagala KKK, Morin-Baxter J, Carvajal R, Cheema M, Dubey S, Nakagawa H, Yoon A, Cheng YL, Taylor A, Nickerson J, Mintz A, Momen-Heravi F. Tanagala KKK, et al. Among authors: carvajal r. J Immunother Cancer. 2022 Dec;10(12):e005088. doi: 10.1136/jitc-2022-005088. J Immunother Cancer. 2022. PMID: 36600652 Free PMC article.
Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J, Lagana SM, Saenger YM, Carvajal RD. Yang J, et al. Among authors: carvajal rd. J Immunother Cancer. 2019 Nov 15;7(1):310. doi: 10.1186/s40425-019-0743-5. J Immunother Cancer. 2019. PMID: 31730503 Free PMC article.
Case of Merkel cell carcinoma in a patient with pre-existing ILD.
Maniar R, Anderson M, Taback B, Khan S, McDonnell D, Saqi A, Niedt GW, Carvajal R. Maniar R, et al. Among authors: carvajal r. J Immunother Cancer. 2020 Nov;8(2):e001672. doi: 10.1136/jitc-2020-001672. J Immunother Cancer. 2020. PMID: 33203666 Free PMC article.
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Goldman JW, et al. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016. Clin Cancer Res. 2022. PMID: 35699623
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, Hershman DL, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. Mundi PS, et al. Among authors: carvajal rd. Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020. Cancer Discov. 2023. PMID: 37061969 Free PMC article.
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. Najjar YG, et al. Among authors: carvajal r. J Immunother Cancer. 2020 Jun;8(1):e000331. doi: 10.1136/jitc-2019-000331. J Immunother Cancer. 2020. PMID: 32581057 Free PMC article.
366 results